BriefingWire - Trusted Press Release Submission

Trusted Press Release Distribution

Plans | Login

Briefing Search

Keyword:
Category:

	Sharing Options
	Marlon Nurse marlon@plrinvest.com 564-4700 7 Penn Plaza

Provectus Biopharmaceuticals
created on: 10/01/2014

pvct.com
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov.

Latest Briefings:

Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas 135 views

10/01/2014, Data Presented at the European Society for Medical Oncology Congress in Spain Shows New Approach offers Overall Response Rate of 71% read more

FAQs | Contact Us | Terms & Conditions | Privacy Policy